Piletta-Zanin Aurélie, Hsieh Aurélie, Mühlstädt Michael, Andenmatten-Trigona Béatrice
Faculté de médecine, Université de Genève, 1211 Genève 4.
Service de dermatologie et vénéréologie, Département des spécialités de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14.
Rev Med Suisse. 2022 Feb 2;18(767):156-160. doi: 10.53738/REVMED.2022.18.767.156.
In recent years, a lot of targeted therapies have appeared on the market. The huge choice and rapid development make it sometimes difficult to stay up to date. This article reviews the latest therapies in the field of atopic dermatitis, alopecia areata and chronic spontaneous urticaria. Anti-IL-4 and anti-IL-13 antibodies and, more recently, JAK inhibitors have been proven to be effective for moderate to severe atopic dermatitis. JAK inhibitors seem promising for the treatment of severe alopecia areata. Ligelizumab and nemoli zumab will provide therapeutical options for chronic spontaneous urticaria and prurigo respectively. These breakthroughs will improve the quality of life of people suffering from invalidating dermatitis, at a certain price.
近年来，许多靶向疗法已投放市场。众多的选择和快速的发展使得有时难以跟上最新进展。本文综述了特应性皮炎、斑秃和慢性自发性荨麻疹领域的最新疗法。抗IL-4和抗IL-13抗体，以及最近的JAK抑制剂已被证明对中度至重度特应性皮炎有效。JAK抑制剂在重度斑秃的治疗中似乎很有前景。利吉珠单抗和奈莫利珠单抗将分别为慢性自发性荨麻疹和痒疹提供治疗选择。这些突破将在一定程度上改善患有致残性皮炎患者的生活质量。
